RxElite, Inc. (RXEI)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
RxElite, Inc. (RXEI) trades at $0.00 with AI Score 65/100 (Grade B+). RxElite, Inc. develops, manufactures, and markets generic prescription drugs, including sterile liquid dose, inhalation respiratory, and injectable products. Market cap: $1,483, Sector: Healthcare.
Last analyzed: Mar 17, 2026Analyst Coverage for RXEI: RXEI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates RXEI against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
RXEI: 2/4 perspectives are bearish. Dominant signal: Seth Klarman bearish.
RxElite, Inc. (RXEI) Healthcare & Pipeline Overview
RxElite, Inc. focuses on specialty generic markets, manufacturing sterile liquid dose, inhalation respiratory, and injectable drugs, along with active pharmaceutical ingredients. The company serves hospitals, wholesalers, and pharmacies, operating as a subsidiary of Piramal Healthcare Ltd. in the competitive generic drug landscape.
What Is the Investment Thesis for RXEI?
RxElite, Inc. operates in the niche generic pharmaceutical market, focusing on sterile liquid dose, inhalation, and injectable products. With a negative profit margin of -610.5% and a gross margin of 5.1%, the company faces significant profitability challenges. Key value drivers include expanding its product portfolio and leveraging partnerships with companies like Stason Pharmaceuticals, Alkem Laboratories, and Zach Systems. Growth catalysts involve penetrating new markets and increasing API manufacturing for pharmaceutical companies in the US, Europe, and Asia. However, the company's high beta of 6.40 indicates significant volatility. The company's OTC listing and lack of dividend further contribute to the risk profile. Investors should carefully assess the company's ability to improve profitability and manage its operational costs.
Based on FMP financials and quantitative analysis
RXEI Key Highlights
- RxElite, Inc. operates in the specialty generic drug market, focusing on niche products.
- The company's profit margin is significantly negative at -610.5%, indicating substantial losses.
- Gross margin stands at 5.1%, reflecting low profitability on sales.
- RxElite has a high beta of 6.40, suggesting high volatility compared to the market.
- The company manufactures both finished generic drugs and active pharmaceutical ingredients (APIs).
Who Are RXEI's Competitors?
RXEI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALVO Alvotech | $4.44 | +5.21% | $1.39B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| NBIX Neurocrine Biosciences, Inc. | $161.83 | -0.54% | $16.27B | 65 |
| GDNSF Goodness Growth Holdings, Inc. | $0.45 | +0.00% | $61.05M | 64 |
| AVDL Avadel Pharmaceuticals plc | $21.64 | +0.00% | $2.12B | 64 |
| CPHRF Cipher Pharmaceuticals Inc. | $11.55 | +0.26% | $292.00M | 63 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RXEI's Key Strengths?
- Focus on specialty generic markets.
- Manufacturing capabilities for both finished drugs and APIs.
- Established partnerships with other pharmaceutical companies.
- Operates as a subsidiary of Piramal Healthcare Ltd.
What Are RXEI's Weaknesses?
- Negative profit margin (-610.5%).
- Low gross margin (5.1%).
- High beta (6.40) indicating high volatility.
- OTC listing indicates higher risk and lower liquidity.
What Could Drive RXEI Stock Higher?
- Expansion of product portfolio in sterile liquid dose, inhalation respiratory, and injectable drugs.
- Increased API manufacturing for pharmaceutical companies in the US, Europe, and Asia.
- Strategic partnerships with other pharmaceutical companies for product development and distribution.
- Potential regulatory approvals for new generic drug products.
- Entry into new geographic markets through distribution agreements.
What Are the Key Risks for RXEI?
- Intense competition in the generic pharmaceutical industry.
- Pricing pressures and declining reimbursement rates.
- Regulatory challenges and compliance requirements.
- Product liability claims.
- Negative profit margin and low gross margin.
What Are the Growth Opportunities for RXEI?
- Expansion of Sterile Liquid Dose Products: RxElite can capitalize on the growing demand for generic ophthalmic solutions. The global ophthalmic market is projected to reach $44.7 billion by 2027. By expanding its range of unit and multi-dose presentations, RxElite can target a larger share of this market, particularly focusing on hospitals and outpatient surgery centers. Timeline: 2-3 years.
- Increased API Manufacturing: RxElite can increase its production and sales of active pharmaceutical ingredients (APIs) to pharmaceutical companies in the United States, Europe, and Asia. The global API market is projected to reach $277.28 billion by 2030. By leveraging its manufacturing capabilities and partnerships, RxElite can become a key supplier in the API market. Timeline: 3-5 years.
- Penetration of New Geographic Markets: RxElite can expand its market presence by entering new geographic regions. Focusing on emerging markets with increasing healthcare expenditure can provide significant growth opportunities. This expansion can be achieved through strategic partnerships and distribution agreements. Timeline: 3-5 years.
- Development of New Generic Products: RxElite can invest in the development of new generic prescription drug products, particularly in areas with unmet medical needs. Focusing on specialty generic markets with limited competition can provide higher profit margins. This requires investment in research and development and regulatory approvals. Timeline: 4-6 years.
- Strategic Partnerships and Acquisitions: RxElite can pursue strategic partnerships and acquisitions to expand its product portfolio, market reach, and manufacturing capabilities. Collaborating with other pharmaceutical companies can provide access to new technologies and markets. Timeline: Ongoing.
What Opportunities Does RXEI Have?
- Expansion of sterile liquid dose product line.
- Increased API manufacturing for pharmaceutical companies.
- Penetration of new geographic markets.
- Development of new generic products.
What Threats Does RXEI Face?
- Intense competition in the generic pharmaceutical industry.
- Pricing pressures and declining reimbursement rates.
- Regulatory challenges and compliance requirements.
- Potential product liability claims.
What Are RXEI's Competitive Advantages?
- Specialty Generic Focus: Focus on niche markets with less competition.
- API Manufacturing Capabilities: Ability to manufacture active pharmaceutical ingredients.
- Established Partnerships: Partnerships with Stason Pharmaceuticals, Alkem Laboratories, and Zach Systems.
- Subsidiary of Piramal Healthcare: Access to resources and expertise of a larger pharmaceutical company.
What Does RXEI Do?
RxElite, Inc., headquartered in Meridian, Idaho, specializes in the development, manufacture, and marketing of generic prescription drug products, primarily targeting specialty generic markets. The company's origins trace back to its focus on addressing niche segments within the generic pharmaceutical industry, providing alternatives to branded drugs. RxElite's product portfolio includes Sterile Liquid Dose products, encompassing generic ophthalmic solutions in both unit and multi-dose presentations. Additionally, they offer sterile unit dose inhalation respiratory products and injectable drugs, catering to specific medical needs. Beyond finished drug products, RxElite, through its subsidiaries, manufactures active pharmaceutical ingredients (APIs) for pharmaceutical companies across the United States, Europe, and Asia. This API manufacturing capability allows RxElite to serve as a supplier to other drug manufacturers, diversifying its revenue streams. RxElite serves a diverse customer base, including hospitals and hospital group purchasing organizations (GPOs), national and regional wholesalers, direct retail pharmacy stocking chains, homecare companies, and outpatient surgery centers and ambulatory care clinics. These partnerships enable RxElite to distribute its products through various channels, reaching a wide range of healthcare providers and patients. The company has established partnership agreements with Stason Pharmaceuticals, Inc., Alkem Laboratories Limited, and Zach Systems S.p.A., enhancing its capabilities and market reach. RxElite Inc. operates as a subsidiary of Piramal Healthcare Ltd., a global pharmaceutical company.
What Products and Services Does RXEI Offer?
- Develops generic prescription drug products.
- Manufactures sterile liquid dose products, including ophthalmic solutions.
- Produces sterile unit dose inhalation respiratory products.
- Manufactures injectable drugs.
- Produces active pharmaceutical ingredients (APIs) for other pharmaceutical companies.
- Markets products to hospitals, wholesalers, and pharmacies.
How Does RXEI Make Money?
- Develops and manufactures generic drugs.
- Sells finished drug products to hospitals, wholesalers, and pharmacies.
- Manufactures and sells active pharmaceutical ingredients (APIs) to other pharmaceutical companies.
- Partners with other pharmaceutical companies for product development and distribution.
What Industry Does RXEI Operate In?
RxElite, Inc. operates within the generic pharmaceutical industry, a sector characterized by intense competition and pricing pressures. The global generic drug market is projected to reach $515 billion by 2029, driven by increasing demand for affordable medications and the expiration of patents on branded drugs. RxElite focuses on specialty generic markets, including sterile liquid dose, inhalation, and injectable products. Competitors include companies like BLEVF (Blue Water Vaccines, Inc.), EPRSQ (Encore Energy Corp.), GNRS (Generes Biotech Corp.), GWHP (Greenwood Hall Inc.), and INTP (Intra-Cellular Therapies Inc.). These companies operate in different segments of the healthcare and pharmaceutical industries, but represent the competitive landscape for RxElite.
Who Are RXEI's Key Customers?
- Hospitals and hospital group purchasing organizations (GPOs).
- National and regional wholesalers.
- Direct retail pharmacy stocking chains.
- Homecare companies.
- Outpatient surgery centers and ambulatory care clinics.
RXEI Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
RXEI Latest News
No recent news available for RXEI.
RXEI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for RXEI.
Price Targets
Wall Street price target analysis for RXEI.
RXEI MoonshotScore
What does this score mean?
The MoonshotScore rates RXEI's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Richard Tener
CEO
Richard Tener serves as the CEO of RxElite, Inc., managing a team of 47 employees. Information on his detailed career history and educational background is not available. As CEO, he is responsible for the strategic direction and operational management of the company, focusing on the development, manufacture, and marketing of generic prescription drug products.
Track Record: Due to limited information, Richard Tener's specific achievements and strategic decisions at RxElite, Inc. cannot be detailed. His leadership is focused on navigating the competitive generic pharmaceutical market and improving the company's financial performance.
RXEI OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, characterized by companies that may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance. Investing in companies on the OTC Other tier carries a higher degree of risk compared to those listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure due to OTC Other listing.
- Low trading volume and liquidity.
- Higher price volatility compared to exchange-listed stocks.
- Potential for fraud or manipulation due to less stringent regulatory oversight.
- Difficulty in obtaining accurate and timely information about the company.
- Verify the company's registration and regulatory filings.
- Review available financial statements and assess their accuracy.
- Research the background and experience of the company's management team.
- Evaluate the company's business model and competitive landscape.
- Assess the company's debt levels and cash flow.
- Monitor news and press releases for any red flags.
- Consult with a financial advisor before investing.
- RxElite, Inc. operates as a subsidiary of Piramal Healthcare Ltd., a global pharmaceutical company.
- The company has established partnerships with Stason Pharmaceuticals, Alkem Laboratories, and Zach Systems.
- RxElite manufactures active pharmaceutical ingredients (APIs) for pharmaceutical companies in the United States, Europe, and Asia.
- The company has been in operation for several years, indicating some level of stability.
- RxElite's focus on specialty generic markets suggests a targeted business strategy.
Common Questions About RXEI (Healthcare)
What does RxElite, Inc. do?
RxElite, Inc. develops, manufactures, and markets generic prescription drug products, primarily focusing on specialty generic markets. Their product portfolio includes sterile liquid dose products like ophthalmic solutions, sterile unit dose inhalation respiratory products, and injectable drugs. Additionally, RxElite manufactures active pharmaceutical ingredients (APIs) for other pharmaceutical companies across the United States, Europe, and Asia. They serve a diverse customer base, including hospitals, wholesalers, and pharmacies, distributing their products through various channels.
What do analysts say about RXEI stock?
As of 2026-03-17, there is no available analyst coverage for RXEI stock due to its listing on the OTC Other market and limited financial disclosure. Key valuation metrics such as price targets and earnings estimates are not available. Investors should conduct their own due diligence and consider the company's financial performance, growth opportunities, and risk factors before making any investment decisions. The absence of analyst coverage highlights the higher risk associated with investing in OTC-listed companies.
What are the main risks for RXEI?
RxElite, Inc. faces several risks, including intense competition in the generic pharmaceutical industry, pricing pressures, and declining reimbursement rates. The company's negative profit margin and low gross margin indicate significant financial challenges. Regulatory challenges and compliance requirements pose additional risks. As an OTC-listed company, RXEI faces higher price volatility, lower liquidity, and limited financial disclosure. Investors should carefully consider these risks before investing in RXEI.
What are the key factors to evaluate for RXEI?
RxElite, Inc. (RXEI) holds an AI score of 65/100 (moderate). Not financial advice.
How frequently does RXEI data refresh on this page?
RXEI prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven RXEI's recent stock price performance?
RxElite, Inc. (RXEI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on specialty generic markets. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider RXEI overvalued or undervalued right now?
Valuing RxElite, Inc. (RXEI) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying RXEI?
Before investing in RxElite, Inc. (RXEI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial information available due to OTC listing.
- Analyst coverage is not available for RXEI.